Oppenheimer lowers Intellia Therapeutics stock price target on nex-z trial pause
NegativeFinancial Markets

Oppenheimer has lowered its stock price target for Intellia Therapeutics following the pause in the Nex-Z trial. This development is significant as it reflects concerns about the company's progress and future prospects in the biotech sector, potentially impacting investor confidence and market performance.
— Curated by the World Pulse Now AI Editorial System





